Brighter’s pioneering diabetes management solution Actiste® receives market approval in the United Arab Emirates
Brighter AB (publ) is proud to announce that its pioneering solution for improved diabetes management, Actiste®, has received market approval from the UAE Ministry of Health and Prevention (“MOHAP”). Some additional regulatory approvals for consumables included within the Actiste® Diabetes Management as a Service (“Actiste Service”) offering are still outstanding but underway.
“The market approval in the UAE is a vital milestone allowing Brighter to start engaging with real-world patients and making a difference in their everyday life. We are glad to now be able to actively contribute to the MOHAP’s keenness to develop its practices so as to achieve the highest rates of quality, safety and efficiency of healthcare in UAE,” says Henrik Norström, CEO of Brighter.
In parallel to the market approval process, Brighter’s regional team in Dubai has been showcasing and discussing the Company’s unique Actiste Service offering with a wide range of entities in the UAE, including local and regional health institutions, specialist clinics, health authorities and private companies.
With the market approval now in place, Brighter is determined to move forward with its commercial efforts in the region swiftly. The previously mentioned Actiste User Experience Pilot study, planned to be conducted in cooperation with selected primary healthcare clinics governed by MOHAP, is still under assessment but does not preclude us from deploying the Actiste Service and executing on sales opportunities in the UAE.
The Actiste Service will be sold through a mix of marketing channels including business-to-consumer (B2C), business-to-business (B2B) and business-to-government (B2G). Brighter’s ambition is to make a difference for at least 30% of the potential users in the UAE within the next five years.
The International Diabetes Federation (IDF) warns that the UAE is on course to double the number of people living with diabetes in the country, to approximately 2.2 million by 2040. Diabetes prevalence was estimated at c.16% in 2019.
About Actiste
Actiste is the world's first complete IoT care solution for monitoring and treating insulin-dependent diabetes. The unit brings together and combines all the necessary functions for diabetes care – blood sampling, blood glucose measurement and drug injection – in a single connected device.
The solution is based on patented technology for collecting data on specified biomarkers and injected volumes of drugs. With state-of-the-art eSIM technology, Actiste has global out-of-the-box connectivity, making it completely independent of other devices to utilize and share health and treatment data. Actiste received two CE-marks in September 2019 - one for MDD and one for IVDD.
The Actiste device is delivered as part of a subscription service (“Actiste® Diabetes Management as a Service”). The service includes a digital platform for daily support and management, global connectivity, different levels of data sharing, continuous replenishment of consumables and enables coaching to continuously optimize and improve treatments. https://actiste.com.
For further information, please contact:
Investor Relations
IR@brighter.se
Henrik Norström, CEO
+46 733 40 30 45
henrik.norstrom@brighter.se
Certified Adviser
Brighter’s Certified Adviser is Eminova Fondkommission AB, +46 (0)8 – 684 211 10, adviser@eminova.se, www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is key to provide smarter care for chronic conditions. Our daily-care solutions facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones and their care providers – improving quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter is certified under ISO 13485. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
This information is information that Brighter AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 12:07 CET on November 9, 2020.
